sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model

Acta Physiologica

Volumn 206, Issue 3, 2012, Pages 178-194

  Lundgren, J ^a,b   Kylhammar, D ^a,b,c   Hedelin, P ^a,b,c   Radegran G ^a,b,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

BAY 41 8543; Hypoxia; Pulmonary vasoconstriction; Soluble guanylate cyclase; Tezosentan

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; GUANYLATE CYCLASE; TEZOSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HYPOXIA; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ANIMALS; ANOXIA; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME ACTIVATORS; FEMALE; GUANYLATE CYCLASE; HYPERTENSION, PULMONARY; LUNG; MORPHOLINES; PYRIDINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SWINE; TETRAZOLES; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 84866902404     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2012.02445.x     Document Type: Article

References (47)

1. Aversa, C.R., Oparil, S., Caro, J., Li, H., Sun, S.D., Chen, Y.F., Swerdel, M.R., Monticello, T.M., Durham, S.K., Minchenko, A., Lira, S.A. & Webb, M.L. 1997. Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice. Am J Physiol Lung Cell Mol Physiol 273, L848-L855.
2. Bartsch, P., Mairbaurl, H., Maggiorini, M. & Swenson, E.R. 2005. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol 98, 1101-1110.
3. Biarent, D., Hubloue, I., Bejjani, G., Melot, C., Jespers, P., Naeije, R. & Leeman, M. 2006. Role of endothelins and nitric oxide in the pulmonary circulation of perinatal lambs during hyperoxia and hypoxia. Pediatr Res 59, 131-136.
4. Boerrigter, G. & Burnett, J.C. Jr 2010. Soluble guanylate cyclase: not a dull enzyme. Circulation 119, 2752-2754.
5. Bonvallet, S.T., Zamora, M.R., Hasunuma, K., Sato, K., Hanasato, N., Anderson, D., Sato, K. & Stelzner, T.J. 1994. BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 266, H1327-H1331.
6. Chen, S.J., Chen, Y.-F., Meng, Q.C., Durand, J., DiCarlo, V.S. & Oparil, S. 1995. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79, 2122-2131.
7. Chen, S.J., Chen, Y.-F., Opgenorth, T.J., Wessale, J.L., Meng, Q.C., Durand, J., DiCarlo, V.S. & Oparil, S. 1997. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 29, 713-725.
8. Clozel, M., Volker, B., Gray, G.A., Kalina, B., Löffler, B.-M., Burri, K., Cassal, J.-M., Hirth, G., Müller, M., Neidhart, W. & Ramuz, H. 1994. Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270, 228-235.
9. Clozel, M., Ramuz, H., Clozel, J.P., Breu, V., Hess, P., Loffler, B.M., Coassolo, P. & Roux, S. 1999. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290, 840-846.
10. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol Lung Cell Mol Physiol 269, L690-L697.
11. Douglas, S.A., Vickery-Clark, L.M. & Ohlstein, E.H. 1993. Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123. Br J Pharmacol 108, 418-421.
12. Dumitrascu, R., Weissmann, N., Ghofrani, H.A., Dony, E., Beuerlein, K., Schmidt, H., Stasch, J.P., Gnoth, M.J., Seeger, W., Grimminger, F. & Schermuly, R.T. 2006. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113, 286-295.
13. Elton, T.S., Oparil, S., Taylor, G.R., Hicks, P.H., Yang, R.-H., Jin, H. & Chen, Y.F. 1992. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol Regul Integr Comp Physiol 263, R1260-R1264.
14. von Euler, U.S. & Liljestrand, G. 1946. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand 12, 301-320.
15. Evgenov, O.V., Pacher, P., Schmidt, P.M., Haskó, G., Schmidt, H.H. & Stasch, J.P. 2006. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5, 755-768.
16. Franco-Cereceda, A. & Holm, P. 1998. Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension? J Cardiovasc Pharmacol 31, S447-S452.
17. Galie, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J.S. et al.2009. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30, 2493-2537.
18. Glasser, S.A., Domino, K.B., Lindgren, L., Parcella, P., Marshall, C. & Marshall, B.E. 1983. Pulmonary blood pressure and flow during atelectasis in the dog. Anesthesiology 58, 225-231.
19. B receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction: influence of potassium channels. J Cardiovasc Pharmacol 41, 117-125.
20. Hedelin, P., Kylhammar, D. & Rådegran, G. 2011. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model. Acta Physiol 204, 419-434.
21. Holm, P., Liska, J., Clozel, M. & Franco-Cereceda, A. 1996. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 112, 890-897.
22. A receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo. Cardiovasc Res 37, 765-771.
23. Hubloue, I., Biarent, D., Abdel Kafi, S., Bejjani, G., Kerbaul, F., Naeije, R. & Leeman, M. 2003. Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction. Eur Respir J 21, 19-24.
24. Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M., Christman, B.W., Weir, E.K., Eickelberg, O., Voelkel, N.F. & Rabinovitch, M. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43, 13S-24S.
25. Ignarro, L.J., Adams, J.B., Horwitz, P.M. & Wood, K.S. 1986. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem 261, 4997-5002.
26. Kato, M. & Staub, N.C. 1966. Response of small pulmonary arteries to unilobar hypoxia and hypercapnia. Circ Res 19, 426-440.
27. Kourembanas, S., Marsden, P.A., McQuillan, L.P. & Faller, D.V. 1991. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 88, 1054-1057.
28. Lazor, R., Feihl, F., Waeber, B., Kucera, P. & Perret, C. 1996. Endothelin-1 does not mediate the endothelium-dependent hypoxic contractions of small pulmonary arteries in rats. Chest 110, 189-197.
29. Maggiorini, M., Brunner-La Rocca, H.-P., Peth, S., Fischler, M., Böhm, T., Bernheim, A., Kiencke, S., Bloch, K.E., Dehnert, C., Naeije, R., Lehmann, T., Bärtsch, P. & Mairbäurl, H. 2006. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 145, 497-506.
30. McCulloch, K.M., Docherty, C. & MacLean, M.R. 1998. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br J Pharmacol 123, 1621-1630.
31. Mittendorf, J., Weigand, S., Alonso-Alija, C., Bischoff, E., Feurer, A., Gerisch, M., Kern, A., Knorr, A., Lang, D., Muenter, K. et al.2009. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4, 853-865.
32. Modesti, P.A., Vanni, S., Morabito, M., Modesti, A., Marchetta, M., Gamberi, T., Sofi, F., Savia, G., Mancia, G., Gensini, G.F. & Parati, G. 2006. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation 114, 1410-1416.
33. Oparil, S., Chen, S.J., Meng, Q.C., Elton, T.S., Yano, M. & Chen, Y.F. 1995. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 268, L95-L100.
34. Pàvek, K., Boska, D. & Selecky, F.V. 1964. Measurement of cardiac output by thermodilution with constant rate injection of indicator. Circ Res 15, 311-319.
35. Petersen, B., Deja, M., Bartholdy, R., Donaubauer, B., Laudi, S., Francis, R.C.E., Boemke, W., Kaisers, U. & Busch, T. 2008. Inhalation of the ETA receptor antagonist LU-135252 selectiveley attenuates hypoxic pulmonary vasoconstriction. Am J Physiol Regul Integr Comp Physiol 294, R601-R605.
36. Preston, I.R. 2007. Clinical perspective of hypoxia-mediated pulmonary hypertension. Antioxid Redox Signal 9, 711-721.
37. Sato, K., Oka, M., Hasunuma, K., Ohnishi, M., Sato, K. & Kira, S. 1995. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269, L668-L672.
38. ATP channel. Am J Physiol Lung Cell Mol Physiol 278, L434-L442.
39. Simmoneau, G., Robbins, I.M., Beghetti, M., Channick, R.N., Delcroix, M., Denton, C.P., Elliott, C.G., Gaine, S.P., Gladwin, M.T., Jing, Z.C., Krowka, M.J., Langleben, D., Nakanishi, N. & Souza, R. 2009. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54, 43-54.
40. Soma, S., Takahashi, H., Muramatsu, M., Oka, M. & Fukuchi, Y. 1999. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 20, 620-630.
41. Stasch, J.P., Alonso-Alija, C., Apeler, H., Dembowsky, K., Feurer, A., Minuth, T., Perzborn, E., Schramm, M. & Straub, A. 2002. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135, 333-343.
42. Stasch, J.P., Pacher, P. & Evgenov, O.V. 2011. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123, 2263-2273.
43. Tabrizchi, R. & Ford, C.A. 2003. Haemodynamic effects of endothelin receptor antagonist, tezosentan, in tumour necrosis factor-a treated anaesthetized rats. Naunyn-Schmiedeberg's Arch Pharmacol 367, 156-167.
44. Takeoka, M., Ishizaki, T., Sakai, A., Chang, S.W., Shigemori, K., Higashi, T. & Ueda, G. 1995. Effect of BQ123 on vasoconstriction as a result of either hypoxia or endothelin-1 in perfused rat lungs. Acta Physiol Scand 155, 53-60.
45. Vermeersch, P., Buys, E., Pokreisz, P., Marsboom, G., Ichinose, F., Sips, P., Pellens, M., Gillijns, H., Swinnen, M., Graveline, A., Collen, D., Dewerchin, M., Brouckaert, P., Bloch, K.D. & Janssens, S. 2007. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation 116, 936-943.
46. Warnholtz, A., Mollnau, H., Heitzer, T., Kontush, A., Moller-Bertram, T., Lavall, D., Giaid, A., Beisiegel, U., Marklund, S.L., Walter, U., Meinertz, T. & Munzel, T. 2002. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol 40, 1356-1363.
47. Weissmann, N., Hackemack, S., Dahal, B.K., Pullamsetti, S.S., Savai, R., Mittal, M., Fuchs, B., Medebach, T., Dumitrascu, R., van Eickels, M., Ghofrani, H.A., Seeger, W., Grimminger, F. & Schermuly, R.T. 2009. The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 297, L658-L665.